20th May 2015 09:56
LONDON (Alliance News) - Biotherapeutics development company 4d Pharma PLC Wednesday said it has submitted a dossier for its Blautix irritable bowel syndrome treatment to Swissmedic, the Swiss Agency for Therapeutic Products.
4d Pharma said the dossier has been submitted to Swissmedic and EKNZ, the Swiss ethnics committee, in relation to a first study being carried out on healthy volunteers and individuals exhibiting symptoms of irritable bowel syndrome.
The group also said its Thetanix product, for the treatment of Paediatric Crohn's Disease, is progressing towards a first in man study, with trials expected to start in the second half of 2015.
Shares in 4d were up 8.6% to 888.00 pence on Wednesday.
By Sam Unsted; [email protected]; @SamUAtAlliance
Copyright 2015 Alliance News Limited. All Rights Reserved.
Related Shares:
DDDD.L